Lupin, Astellas Settle Mirabegron Patent Case for $90 Million
Indian pharmaceutical company Lupin has agreed to pay Japan’s Astellas Pharma $90 million to resolve a patent infringement dispute over the bladder control medication Mirabegron, allowing Lupin to continue U.S. sales. The payment structure includes a $75 million prepaid option and additional per-unit licensing fees on sales of Mirabegron through Se…